Research programme: paracrine gene therapy - RenovaAlternative Names: RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - Renova
Latest Information Update: 15 Dec 2016
At a glance
- Originator University of California, San Diego
- Developer Renova Therapeutics
- Class Gene therapies
- Mechanism of Action Adenylate cyclase stimulants; Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus